Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

183.32USD
10:26am EST
Change (% chg)

$-0.23 (-0.13%)
Prev Close
$183.55
Open
$182.89
Day's High
$183.75
Day's Low
$182.75
Volume
154,931
Avg. Vol
1,184,245
52-wk High
$201.23
52-wk Low
$152.16

Select another date:

Wed, Feb 14 2018

BRIEF-Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of Blincyto

* AMGEN ANNOUNCES FDA ADVISORY COMMITTEE MEETING TO REVIEW POTENTIAL NEW USE OF BLINCYTO® (BLINATUMOMAB)

Amgen profit misses Street view; sees broad tax reform benefits

Amgen Inc on Thursday reported a fourth-quarter profit well below Wall Street estimates, hurt by a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its shares fell nearly 2 percent.

UPDATE 3-Amgen profit misses Street view; sees broad tax reform benefits

Feb 1 Amgen Inc on Thursday reported a fourth-quarter profit well below Wall Street estimates, hurt by a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its shares fell nearly 2 percent.

Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view

Feb 1 Amgen Inc on Thursday reported fourth-quarter profit well below Wall Street estimates, as a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses hit results.

BRIEF-Amgen Inc Q4 Loss Per Share $5.89

* AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS PER SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT

BRIEF-Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To Kyprolis Label

* AMGEN RECEIVES CHMP POSITIVE OPINION TO ADD UPDATED OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:

BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints

* AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS

BRIEF-European Commission Approves Amgen, Allergan's Mvasi

* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER

BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label

* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL

BRIEF-Biocartis And Amgen Sign New Agreement

* REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND

Select another date: